Cocrystal Pharma, Inc. appointed James Sapirstein as Chief Executive Officer, effective June 3, 2026. Mr. Sapirstein's compensation package includes an annual base salary of $265,000, a 50% performance bonus target, and an initial grant of 235,000 stock options with a $1.05 exercise price. He replaces Co-CEOs Sam Lee and James Martin, who will remain in their roles as President/Chief Scientific Officer and Chief Financial Officer, respectively. Cocrystal Pharma, Inc. is a biopharmaceutical company.